ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Hanmi Pharmaceutical Co., Ltd.

Business Summary

Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for high blood pressure, hyperlipidemia, reflux esophagitis, and cerebrovascular disease. The company was founded by Lim Sung-Gi on June 15, 1973 and is headquartered in Hwaseong, South Korea.

Financial Highlights

Dec 2020 KRWUSD
Revenue1,075.85B911.82M
Gross Profit584,885.02M495.71M
Operating income48,976.34M41.50M
Income before tax22,130.41M18.75M
Net income11,959.25M10.13M
EBITDA110,315.40M93.49M
Diluted EPS996.690.84
Dividends Per Share490.190.41
Total Assets1,882.02B1,732.51M
Total liabilities1,050.13B966.70M
Total equity729,987.42M671.99M
Operating cash flow151,534.94M128.43M
Currency in KRWCurrency in USD

Historical Data

 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 882,724.83M 916,586.23M 1,015.96B 1,113.64B 1,075.85B
Gross Profit 442,522.46M 511,632.88M 552,497.93M 639,826.90M 584,885.02M
Operating income 26,771.86M 82,163.67M 83,646.47M 103,877.84M 48,976.34M
Income before tax 7,997.73M 58,849.50M 50,354.80M 83,269.64M 22,130.41M
Net income 23,325.62M 60,434.21M 24,891.11M 52,109.66M 11,959.25M
EBITDA 65,546.52M 119,135.28M 130,767.17M 159,290.01M 110,315.40M
Diluted EPS 1,935.75 5,165.81 2,073.84 4,254.08 996.69
Dividends Per Share 0 461.92 471.16 480.58 490.19
Total Assets 1,596.97B 1,660.93B 1,691.20B 1,913.70B 1,882.02B
Total liabilities 862,453.63M 868,509.82M 901,953.19M 1,091.44B 1,050.13B
Total equity 659,461.20M 711,710.95M 703,228.12M 723,795.03M 729,987.42M
Operating cash flow 419,187.50M -62,905.20M 25,982.25M 12,446.62M 151,534.94M
 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 760.84M 810.77M 923.16M 954.95M 911.82M
Gross Profit 381.42M 452.56M 502.03M 548.64M 495.71M
Operating income 23.07M 72.67M 76.00M 89.07M 41.50M
Income before tax 6.89M 52.05M 45.75M 71.40M 18.75M
Net income 20.10M 53.45M 22.61M 44.68M 10.13M
EBITDA 56.49M 105.38M 118.82M 136.59M 93.49M
Diluted EPS 1.66 4.56 1.88 3.64 0.84
Dividends Per Share 0 0.40 0.42 0.41 0.41
Total Assets 1,322.21M 1,551.47M 1,515.69M 1,654.81M 1,732.51M
Total liabilities 714.06M 811.27M 808.34M 943.78M 966.70M
Total equity 546.00M 664.80M 630.24M 625.87M 671.99M
Operating cash flow 361.30M -55.64M 23.60M 10.67M 128.43M

Valuation Measures

Dec 2020
PER367.71
ROA0.63%
ROE1.64%
Operating margin4.55%
Profit margin1.11%

Key executives

  • Co-President, Co-CEO & Director: Se-Chang Kwon
  • Co-President, Co-CEO & Director: Jong-Su Woo
  • Co-President, Director & Head-Business Development: Jong-Yoon Lim
  • Senior Managing Director & Head-Research Center: Gwi-Hyun Seo
  • Compliance Officer & Head-Audit Team: In-Guk Hwang

Shareholders

  • Hanmi Science Co., Ltd. (41.3%)
  • National Pension Service of Korea (8.8%)
  • SHIN DONG-GUK (7.7%)
  • The Vanguard Group, Inc. (1.4%)
  • BlackRock Fund Advisors (1.3%)
  • Hanmi Pharmaceutical Co., Ltd. (0.6%)
  • Norges Bank Investment Management (0.4%)
  • Samsung Asset Management Co., Ltd. (0.4%)
  • Mirae Asset Global Investments Co., Ltd. (0.4%)
  • BlackRock Advisors (UK) Ltd. (0.3%)

Contact Details

Related Companies

  • Hanmi Pharmaceutical Co. Ltd. Esop
  • Hanmi Fine Chemical Co., Ltd.

Competitors

  • Novartis AG
  • Daiichi Sankyo Company, Limited
  • AstraZeneca PLC
  • Sanofi
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk A/S Class B
  • Inventiva SA
  • Zealand Pharma A/S
  • Apellis Pharmaceuticals, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Reyon Pharmaceutical Co., Ltd.
  • Chong Kun Dang Pharmaceutical Corp.
  • Boryung Pharmaceutical Co., Ltd.
  • Kwang Dong Pharmaceutical Co., Ltd.
  • Dong-A ST Co., Ltd.
  • PharmGen Science, Inc.
  • Kyongbo Pharmaceutical Co., Ltd.
  • Hana Pharm Co., Ltd.
  • Jeil Pharmaceutical Co. Ltd.
  • Binex Co., Ltd
  • JEIL PHARMA HOLDINGS INC.
  • KUKJE PHARMA Co., Ltd.
  • IL DONG PHARMACEUTICAL CO., LTD.
  • YUNGJIN PHARM. CO. LTD
  • Shinpoong Pharmaceutical Co., Ltd.
  • Whan In Pharmaceutical Co., Ltd.
Last Updated on 17 Sep, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more